Kinetics of intravenous metoclopramide in patients with hepatic cirrhosis

F. Albani, M. R. Tamè, R. De Palma, M. Bernardi

Research output: Contribution to journalArticlepeer-review


The pharmacokinetics of metoclopramide has been studied after acute IV administration to 12 patients with hepatic cirrhosis (6 with and 6 without ascites) and 6 control subjects. The elimination half-life was significantly longer in patients (11.4 h and 9.9 h in those with and without ascites, respectively, vs 6.4 h in controls). Total plasma clearance was significantly lower in patients (0.29 and 0.36 l·kg-1·h-1 vs 0.52 l·kg-1·h-1 in controls). The differences between patients with and without ascites did not reach statistical significance. Reduction of functional hepatic blood flow in cirrhotic patients is the probable cause of the observed alteration in metoclopramide kinetics.

Original languageEnglish
Pages (from-to)423-425
Number of pages3
JournalEuropean Journal of Clinical Pharmacology
Issue number4
Publication statusPublished - Apr 1991


  • Cirrhosis
  • Metoclopramide
  • Pharmacokinetics
  • side effects

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Pharmacology (medical)


Dive into the research topics of 'Kinetics of intravenous metoclopramide in patients with hepatic cirrhosis'. Together they form a unique fingerprint.

Cite this